Precigen Inc stock is traded at $4.47, with a volume of 9,231,418. It is up +5.92% in the last 24 hours and down -40.79% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Previous Close:
$4.22
Open:
$4.32
24h Volume:
9,231,418
Relative Volume:
0.90
Market Cap:
$1.60B
Revenue:
$9.68M
Net Income/Loss:
-$250.64M
P/E Ratio:
-
EPS:
-$1.40
Net Cash Flow:
-$89.83M
1W Performance:
-35.59%
1M Performance:
-40.79%
6M Performance:
+1.59%
1Y Performance:
+14.03%
1-Day Range:
$4.03$4.48
1-Week Range:
$3.92$5.48
52-Week Range:
$3.04$8.98
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen IncSector
HealthcareIndustry
BiotechnologyPhone
301-556-9900Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS